The Role of Dynorphin and the Kappa Opioid Receptor in the Symptomatology of Schizophrenia: A Review of the Evidence
![Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists](https://www.frontiersin.org/files/Articles/447554/fphar-10-00407-HTML/image_m/fphar-10-00407-g002.jpg)
Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
![The blocking of kappa‐opioid receptor reverses the changes in dorsolateral striatum dopamine dynamics during the amphetamine sensitization - Azocar - 2019 - Journal of Neurochemistry - Wiley Online Library The blocking of kappa‐opioid receptor reverses the changes in dorsolateral striatum dopamine dynamics during the amphetamine sensitization - Azocar - 2019 - Journal of Neurochemistry - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/949a9b01-3f7c-4aa7-bc00-2e80cd815320/jnc14612-fig-0005-m.jpg)
The blocking of kappa‐opioid receptor reverses the changes in dorsolateral striatum dopamine dynamics during the amphetamine sensitization - Azocar - 2019 - Journal of Neurochemistry - Wiley Online Library
![A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics - ScienceDirect A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0031942217300420-fx1.jpg)
A unique natural selective kappa-opioid receptor agonist, salvinorin A, and its roles in human therapeutics - ScienceDirect
![Nephrology Journal Club on Twitter: "Difelikefalin (CR845) (KORSUVA) is a peripherally restricted, selective kappa opioid receptor agonist that exerts antipruritic effects by means of activation of kappa opioid receptors on peripheral neurons Nephrology Journal Club on Twitter: "Difelikefalin (CR845) (KORSUVA) is a peripherally restricted, selective kappa opioid receptor agonist that exerts antipruritic effects by means of activation of kappa opioid receptors on peripheral neurons](https://pbs.twimg.com/media/EJQpY99U4AY2hKN.jpg)
Nephrology Journal Club on Twitter: "Difelikefalin (CR845) (KORSUVA) is a peripherally restricted, selective kappa opioid receptor agonist that exerts antipruritic effects by means of activation of kappa opioid receptors on peripheral neurons
![Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists](https://www.frontiersin.org/files/Articles/447554/fphar-10-00407-HTML/image_m/fphar-10-00407-g001.jpg)
Frontiers | A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists
![Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor | Journal of Medicinal Chemistry Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.7b00109/asset/images/large/jm-2017-00109c_0010.jpeg)
Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor | Journal of Medicinal Chemistry
![Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/ff659c0a-df99-4a5e-8df9-c1e1925ea7d0/jcpt12404-fig-0001-m.jpg)
Will peripherally restricted kappa‐opioid receptor agonists (pKORAs) relieve pain with less opioid adverse effects and abuse potential? - Albert‐Vartanian - 2016 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
![Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA) Targeting the Kappa Opioid Receptor to Reduce Drug Use and Relapse | National Institute on Drug Abuse (NIDA)](https://nida.nih.gov/sites/default/files/styles/content_image_medium/public/images/valenza_zamarripa_promo.jpg?itok=HRbtRBEw)